Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 4/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917442 | 0.85 | BRD4 (0.35) | BRD4MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL916224 | 0.80 | L3MBTL1 (0.34) | BRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL711459 | 0.80 | TP53 (0.49) | HTR6TP53MEN1KMT2ATHRB | |
| SCHEMBL916636 | 0.78 | MDM2 (0.42) | HTR6MDM2TP53MEN1KMT2A | |
| SCHEMBL916634 | 0.78 | KMT2A (0.42) | HTR6MDM2TP53MEN1KMT2A | |
| SCHEMBL716247 | 0.78 | SLC6A4 (0.33) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL916862 | 0.77 | BRD4 (0.37) | BRD4MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL916278 | 0.76 | SLC6A4 (0.36) | BRD4TP53RXFP1ALDH1A1LMNA | |
| SCHEMBL916638 | 0.75 | BRD4 (0.39) | BRD4MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL916730 | 0.75 | BRD4 (0.39) | BRD4TP53MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1742912-A1 | NOVEL ANDROGENS | N.V. Organon (NL) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | HTR6 734/4885MET 642/4885MDM2 1583/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | HTR6 209/4885MET 587/4885MDM2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.